James Muir

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry

Giuseppe Boriani, Marco Proietti, Cécile Laroche et al. · EP Europace · 2019 · 82 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis

Aimilios Lallas, Philipp Tschandl, W. Stolz et al. · British Journal of Dermatology · 2015 · 80 citations

Medicine, Dermatology, Pathology +17

Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

Giulio Francesco Romiti, Marco Proietti, Marco Vitolo et al. · BMC Medicine · 2022 · 70 citations · Full text

Medicine, Cardiology, Internal Medicine +16